RegeneRx Biopharmaceuticals, Inc.
RGRX · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -331.47 | 43.47 | -38.20 |
| FCF Yield | -0.01% | -0.01% | -0.01% | -0.01% |
| EV / EBITDA | -4,944.86 | -12,871,386.64 | 4,342,570.72 | -14,085,927.13 |
| Quality | ||||
| ROIC | 76.64% | 364.71% | -165.89% | -149.52% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.49 | 0.48 | 0.62 | 0.40 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.00% | 0.00% | -0.00% | -0.00% |
| Free Cash Flow Growth | -0.97% | 17.84% | -4.38% | 28.61% |
| Safety | ||||
| Net Debt / EBITDA | -4.57 | -7,454.38 | 1,965.97 | -3,490.42 |
| Interest Coverage | -3.80 | -3.76 | -3.46 | -5.73 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |